|
WO2015121769A1
|
|
Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
|
|
WO2015114479A1
|
|
Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate
|
|
WO2015092687A2
|
|
Process for the purification of darapladib
|
|
WO2015087262A1
|
|
Process for the preparation of saxagliptin and its intermediates
|
|
WO2015092624A1
|
|
Nilotinib mono-oxalate and its crystalline form
|
|
WO2015087239A1
|
|
Processes for the preparation of darapladib and its intermediates
|
|
WO2015087240A1
|
|
Process for the preparation of linagliptin and an intermediate thereof
|
|
WO2015087241A1
|
|
Crush-resistant solid oral dosage form
|
|
WO2015092617A1
|
|
Processes and intermediates for the preparation of enzalutamide
|
|
WO2015092602A1
|
|
Topical pharmaceutical composition of a retinoid
|
|
EP2881116A1
|
|
Febuxostat composition
|
|
US2015150814A1
|
|
Stable oral pharmaceutical composition of solifenacin
|
|
US2016143923A1
|
|
Low dose pharmaceutical composition of doxycycline
|
|
WO2015071889A1
|
|
Oral compositions of saxagliptin
|
|
WO2015071887A1
|
|
Oral pharmaceutical compositions of saxagliptin
|
|
WO2015071859A1
|
|
Oral dispersible composition of a dpp-iv inhibitor
|
|
WO2015063720A1
|
|
Process for the preparation of enzalutamide
|
|
WO2015063709A1
|
|
Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
|
|
WO2015056219A1
|
|
Process for simultaneous drying and micronization of valsartan
|
|
WO2015040605A1
|
|
Crystalline form of mirabegron
|
